AstraZeneca amends collaboration with Ironwood for Linzess in China
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclotide), a first-in-class new treatment for patients with irritable bowel syndrome with constipation (IBS-C).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
More News: AstraZeneca | China Health | Constipation | Hong Kong Health | Irritable Bowel Syndrome | Macau Health | Pharmaceuticals